Endovia Health Sciences, Inc. (EDVA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 19, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the EDVA SEC filings page.
Endovia Health Sciences, Inc. (EDVA) reported $73K in revenue for fiscal year 2025, down 90.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Endovia Health Sciences, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Endovia Health Sciences, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Key Financial Metrics
Earnings & Revenue
Endovia Health Sciences, Inc. reported -$2.1M in net income in Q2 2026. This represents an increase of 75.8% from the same quarter a year earlier. Against the prior quarter it is up 3.8%.
Endovia Health Sciences, Inc. earned -$0.77 per diluted share (EPS) in Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Endovia Health Sciences, Inc. held $243K in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
EDVA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $4K-93.8% | N/A | N/A | N/A | $69K-95.5% | N/A | $982K-80.9% |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | $469K-66.0% | N/A | $691K-82.0% |
| Gross Profit | N/A | $2K+100.5% | N/A | N/A | N/A | -$400K-344.5% | N/A | $291K-77.6% |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $55K-98.2% |
| Operating Income | -$2.0M-33.6% | -$979K+41.0% | N/A | -$9.5M-257.5% | -$1.5M+59.3% | -$1.7M+49.0% | N/A | -$2.7M+38.3% |
| EBITDA | N/A | -$977K+41.0% | N/A | -$9.5M-275.1% | -$1.5M+58.8% | -$1.7M+46.8% | N/A | -$2.5M+39.5% |
| Interest Expense | $231K-63.0% | $889K+39.6% | N/A | $320K-64.1% | $625K+0.5% | $637K+19.7% | N/A | $890K+302.0% |
| Income Tax | $0 | $0 | N/A | $0 | $0 | $0 | N/A | $0 |
| Net Income | -$2.1M+75.8% | -$2.1M+41.5% | N/A | -$9.9M-109.5% | -$8.5M-59.4% | -$3.7M+21.8% | N/A | -$4.7M+16.8% |
| EPS (Basic) | -$0.77+95.7% | -$0.47+76.1% | -$0.40+93.6% | -$4.51-27.0% | -$17.88-312.0% | -$1.97+52.8% | -$6.29-4738.5% | -$3.55-2630.8% |
| EPS (Diluted) | -$0.77 | -$0.47 | -$0.40 | -$4.51 | -$17.88 | -$1.97 | -$6.29 | -$3.55 |
| Diluted Shares (Avg) | 3M | 5M | N/A | 2M | 474,969 | 2M | N/A | 1M |
Not reported in any period shown, so not listed: R&D Expenses.
EDVA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.1M-95.2% | $770K-69.3% | $966K-65.0% | $22.5M+168.9% | $22.2M+176.0% | $2.5M-70.7% | $2.8M-72.1% | $8.4M-25.6% |
| Current Assets | $900K-43.9% | $709K-58.2% | $632K-66.8% | $2.0M-35.2% | $1.6M-36.7% | $1.7M-40.2% | $1.9M-52.1% | $3.0M-40.6% |
| Cash & Equivalents | $243K+1310.0% | $381K | $281K+1941.0% | $266K-41.9% | $17K+107.4% | N/A | $14K-96.4% | $457K+375.3% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | N/A | $0 | $0 |
| Inventory | $55K-93.6% | $55K-93.6% | $34K-89.5% | $855K-36.2% | $855K-34.5% | $861K-41.5% | $319K-85.8% | $1.3M-53.9% |
| Accounts Receivable | $14K-89.8% | $20K-88.2% | $16K-91.8% | $140K-76.6% | $141K-79.0% | $173K-77.1% | $192K-78.4% | $595K-60.6% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | N/A | $0 | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $257K0.0% |
| Total Liabilities | $16.8M+24.5% | $17.0M-24.7% | $16.3M-24.0% | $15.7M-18.1% | $13.5M-26.6% | $22.5M+24.8% | $21.4M+38.0% | $19.2M+61.3% |
| Current Liabilities | $16.8M+25.1% | $17.0M-16.9% | $16.3M-16.1% | $15.6M-12.0% | $13.4M-20.1% | $20.4M+19.9% | $19.4M+31.3% | $17.8M+59.8% |
| Non-Current Liabilities | $0-100.0% | $857-100.0% | $6K-99.7% | $70K-95.1% | $73K-95.4% | $2.1M+104.1% | $2.0M+168.6% | $1.4M+82.8% |
| Long-Term Debt | N/A | $857-100.0% | $3K-99.8% | $58K-95.6% | $53K-96.3% | $2.1M+157.0% | $2.0M+330.7% | $1.3M+223.6% |
| Total Equity | -$15.7M-280.6% | -$16.2M+19.1% | -$15.3M+17.9% | $6.8M+162.6% | $8.7M+184.2% | -$20.0M-110.8% | -$18.6M-232.4% | -$10.8M-1546.0% |
| Retained Earnings | -$186.8M-11.2% | -$184.4M-15.6% | -$181.9M-16.7% | -$178.3M-21.5% | -$168.0M-18.2% | -$159.5M-16.6% | -$155.8M-16.9% | -$146.8M-15.3% |
EDVA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.1M-98.1% | -$930K-15.2% | -$991K-7.8% | -$2.5M+6.6% | -$551K+77.3% | -$808K+38.2% | -$920K+45.4% | -$2.6M-33.5% |
| Depreciation & Amortization | N/A | $2K0.0% | -$102K-2635.7% | $37K-72.6% | $37K-72.6% | $2K-98.3% | -$4K-102.6% | $135K-0.9% |
| Stock-Based Compensation | $1.1M+1956.4% | $177K+30.4% | N/A | $7.8M+4052.3% | $54K-96.0% | $136K-75.6% | N/A | $187K-49.2% |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$920K+45.5% | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | $0+100.0% | -$5K |
| Financing Cash Flow | $1.2M+65.9% | $1.1M+39.4% | $978K-15.6% | $2.7M-11.3% | $696K-71.2% | $756K-20.5% | $1.2M-41.4% | $3.0M+163.2% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
EDVA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | 43.8% | N/A | N/A | N/A | -583.2% | N/A | 29.6%+4.4pp |
| Operating Margin | N/A | -23176.4% | N/A | N/A | N/A | -2417.1% | N/A | -271.9% |
| Net Margin | N/A | -50579.3% | N/A | N/A | N/A | -5320.9% | N/A | -480.7% |
| Return on Equity | N/A | N/A | N/A | -145.9% | -97.4% | N/A | N/A | N/A |
| Return on Assets | -190.9%-152.7pp | -277.5%-132.0pp | N/A | -44.0%+12.5pp | -38.2%+27.9pp | -145.5%-90.9pp | N/A | -56.4%-6.0pp |
| Current Ratio | 0.05-0.1x | 0.040.0x | 0.04-0.1x | 0.130.0x | 0.120.0x | 0.08-0.1x | 0.10-0.2x | 0.17-0.3x |
| Debt-to-Equity | N/A | N/A | N/A | 0.01 | 0.01 | N/A | N/A | N/A |
| Asset Turnover | N/A | 0.010.0x | N/A | N/A | N/A | 0.03-0.2x | N/A | 0.12-0.3x |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$15.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where Endovia Health Sciences, Inc. Ranks
Frequently Asked Questions
What is Endovia Health Sciences, Inc.'s annual revenue?
Endovia Health Sciences, Inc. (EDVA) reported $73K in total revenue for fiscal year 2025. This represents a -90.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Endovia Health Sciences, Inc.'s revenue growing?
Endovia Health Sciences, Inc. (EDVA) revenue declined by 90.9% year-over-year, from $801K to $73K in fiscal year 2025.
How much debt does Endovia Health Sciences, Inc. have?
As of fiscal year 2025, Endovia Health Sciences, Inc. (EDVA) had $281K in cash and equivalents against $3K in long-term debt.
What is Endovia Health Sciences, Inc.'s gross margin?
Endovia Health Sciences, Inc. (EDVA) had a gross margin of 23.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Endovia Health Sciences, Inc.'s operating cash flow?
Endovia Health Sciences, Inc. (EDVA) recorded an outflow of $4.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Endovia Health Sciences, Inc.'s total assets?
Endovia Health Sciences, Inc. (EDVA) had $966K in total assets as of fiscal year 2025, including both current and long-term assets.
What is Endovia Health Sciences, Inc.'s current ratio?
Endovia Health Sciences, Inc. (EDVA) had a current ratio of 0.04 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Endovia Health Sciences, Inc.'s P/E ratio?
Endovia Health Sciences, Inc. (EDVA) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $1.1M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Endovia Health Sciences, Inc.'s price-to-sales ratio?
Endovia Health Sciences, Inc. (EDVA) trades at 15.2x sales, its market capitalization divided by revenue of $73K revenue, FY2025. The market capitalization is $1.1M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Endovia Health Sciences, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Endovia Health Sciences, Inc. (EDVA) held $281K in cash, cash equivalents and investments, and reported an operating cash outflow of $4.8M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Endovia Health Sciences, Inc.'s debt-to-equity ratio negative or not reported?
Endovia Health Sciences, Inc. (EDVA) has negative shareholder equity of -$15.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Endovia Health Sciences, Inc.'s Piotroski F-Score?
Endovia Health Sciences, Inc. (EDVA) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.